{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-015913","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.082214+00:00","generated_at":"2026-06-06T01:19:45.229174+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prelude Therapeutics reports FY2023 net loss of $121.8M; cash runway into 2026, pipeline milestones set for 2024","bullets":["Cash and marketable securities $232.9M as of Dec 31, 2023, expected to fund operations into 2026.","Net loss $121.8M ($2.02/share) for FY2023 vs $115.4M ($2.44/share) for FY2022.","R&D expenses increased to $103.4M from $92.9M; G&A expenses decreased to $28.9M from $30.7M.","PRT3789 (SMARCA2 degrader) on track for monotherapy dose escalation mid-2024; combo with docetaxel initiated H1 2024.","PRT2527 (CDK9 inhibitor) to initiate combo with zanubrutinib Q1 2024; PRT7732 (oral SMARCA2 degrader) IND filing H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-015913","json":"https://secwatch.observer/filing/0000950170-24-015913.json","markdown":"https://secwatch.observer/filing/0000950170-24-015913.md","text":"https://secwatch.observer/filing/0000950170-24-015913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024015913/0000950170-24-015913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024015913/prld-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:19:45.229174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16725ad4be0944bbc972b857fa5f7e544e26fbad","claim":"Prelude Therapeutics Inc reported financial results for the fiscal year ended December 31, 2023.","evidence_excerpt":"Prelude Therapeutics Incorporated (the \"Company\") issued a press release announcing its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024015913/0000950170-24-015913-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}